Chapter 31. Management of the neurogenic bladder: current status and recent developments.
D000892:Anti-Infective Agents, Urinary / Q000627:therapeutic use; D001626:Bethanechol Compounds / Q000627:therapeutic use; D003191:Comprehensive Health Care; D003711:Demyelinating Diseases / Q000150:complications; D006801:Humans; D009128:Muscle Spasticity / Q000150:complications; D010276:Parasympatholytics / Q000627:therapeutic use; D013118:Spinal Cord Diseases / Q000150:complications; D013119:Spinal Cord Injuries / Q000150:complications; D013120:Spinal Cord Neoplasms / Q000150:complications; D001750:Urinary Bladder, Neurogenic / Q000188:drug therapy / Q000209:etiology / Q000601:surgery / Q000628:therapy*; D014546:Urinary Catheterization; D014547:Urinary Diversion; D014552:Urinary Tract Infections / Q000517:prevention & control
D000892:Anti-Infective Agents, Urinary; D001626:Bethanechol Compounds; D010276:Parasympatholytics